Tirzepatide Tested in Teens With Obesity and Related Health Conditions
Tests tirzepatide with healthy eating and exercise in adolescents with obesity.
Plain-language title generated from the registry record
Registry title: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Key facts
- Where
- Buenos Aires, Ramos Mejía, and SAN M. de Tucuman, ArgentinaSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers with obesity and at least 2 weight-related health problems. It tests tirzepatide against placebo, together with healthy eating and physical activity.
- Age
- 12 to 17 years
- Sex
- Girls and boys can both join.
- Disease stage
- Body mass index (BMI) at or above the 95th percentile for age and sex, plus at least 2 of these: hypertension, prediabetes, hypertriglyceridemia.
- Earlier treatment
- At least 1 self-reported unsuccessful dietary effort to lose weight. Weight reduction procedures such as gastric bypass or sleeve gastrectomy are not allowed.
- Biomarker or test result
- HbA1c must not be above 6.4% (46 mmol/mol) at screening.
Main reasons for not taking part
- A weight reduction procedure done or planned during the study
- Weight loss of more than 5 kg (11 lbs) in the 90 days before screening
- Type 1 diabetes, or type 2 diabetes, or HbA1c above 6.4% (46 mmol/mol) at screening
- History of chronic or acute pancreatitis
- Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Source: NCT06439277, who can take part
Where in Argentina
- Centro de Investigaciones Metabólicas (CINME)Buenos Aires, ArgentinaNo longer taking part
- Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaNo longer taking part
- Fundacion RespirarBuenos Aires, ArgentinaNo longer taking part
- Investigaciones Medicas Imoba SrlBuenos Aires, ArgentinaNo longer taking part
- DIM Clínica PrivadaRamos Mejía, ArgentinaNo longer taking part
- Centro de Investigaciones Médicas TucumanSAN M. de Tucuman, ArgentinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06439277
- Record updated
- 24 September 2026
- Original description
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.Read full original descriptionShow less
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.
Inclusion: Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia; Have history of at least 1 self-reported unsuccessful dietary effort to lose weight; Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).
Exclusion: Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to; gastric bypass; sleeve gastrectomy; restrictive bariatric surgery, such as Lap-Band gastric banding, or; any other procedure intended to result in weight reduction; Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records; Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state; Have a history of chronic or acute pancreatitis; Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; Have type 2 diabetes or have a HbA1c > 6.4% at screening.